Avirmax Biopharma Inc.
🇺🇸United States
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
Phase 1
Recruiting
- Conditions
- Neovascular (Wet) AMD
- Interventions
- Drug: ABI-110 High DoseDrug: ABI-110 Low DoseDrug: ABI-110 Medium Dose
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Avirmax Biopharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT06550011
- Locations
- 🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Retina Consultants of Texas - San Antonio, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath